• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

先天性中胚层肾瘤中的 ETV6-NTRK3:SIOP/GPOH 肾母细胞瘤研究报告。

ETV6-NTRK3 in congenital mesoblastic nephroma: A report of the SIOP/GPOH nephroblastoma study.

机构信息

Kiel Pediatric Tumor Registry, Department of Pediatric Pathology, Christian-Albrechts-University Kiel, Kiel, Germany.

Department of Pediatric Hematology and Oncology, University Medical Center Homburg/Saar, Homburg, Germany.

出版信息

Pediatr Blood Cancer. 2018 Apr;65(4). doi: 10.1002/pbc.26925. Epub 2017 Dec 29.

DOI:10.1002/pbc.26925
PMID:29286563
Abstract

BACKGROUND

Congenital mesoblastic nephroma (MN) is a rare pediatric renal tumor representing approximately 5% of all pediatric renal tumors. Three different types of MN are distinguished histologically: classical, cellular, and mixed. A frequent genetic alteration is the translocation t(12;15) resulting in a fusion of the ETV6 gene on 12p13 and the NTRK3 gene on 15p15 that occurs almost exclusively in cellular MN. The aim of this study was to determine translocation status of a large cohort of MN with respect to tumor subtype and outcome.

PROCEDURE

In total, clinical data from 111 patients were available. Sixty-seven tumors were classical MN (51%), 29 cellular MN (31%), and 15 were mixed MN (18%). From these 111 cases, 79 were analyzed by FISH and RT-PCR.

RESULTS

All classical and mixed MN were translocation negative. Seventeen out of 29 (58%) cellular MN harbored the ETV6-NTRK3 translocation. Five-year relapse-free survival (RFS) and overall survival (OS) were 93.2% and 96.8% for the complete cohort. All seven relapses occurred in translocation negative tumors. Five-year RFS was significantly inferior for cellular and mixed MN compared to classic MN (89%, 80%, and 98%), whereas 5-year OS was similar (93%, 96%, and 98%). Within the group of cellular MN, patients having translocation-positive tumors had a significantly superior RFS (5-year RFS: 100% vs. 73%).

CONCLUSION

The majority of cellular MNs harbor the ETV6-NTKR3 gene fusion, whereas all classic- and mixed-type MNs were translocation negative. Within the cellular subgroup, patients having translocation-positive tumors had a significantly superior RFS.

摘要

背景

先天性中胚层肾瘤(MN)是一种罕见的儿科肾肿瘤,约占所有儿科肾肿瘤的 5%。MN 在组织学上可分为三种不同类型:经典型、细胞型和混合型。一种常见的遗传改变是易位 t(12;15),导致 12p13 上的 ETV6 基因和 15p15 上的 NTRK3 基因融合,这种融合几乎只发生在细胞型 MN 中。本研究的目的是确定 MN 的大样本肿瘤亚型和预后的易位状态。

方法

共获得 111 例患者的临床资料。67 例肿瘤为经典 MN(51%),29 例为细胞型 MN(31%),15 例为混合 MN(18%)。从这 111 例中,79 例通过 FISH 和 RT-PCR 进行了分析。

结果

所有经典型和混合型 MN 均为易位阴性。29 例细胞型 MN 中有 17 例(58%)存在 ETV6-NTRK3 易位。全组 5 年无复发生存率(RFS)和总生存率(OS)分别为 93.2%和 96.8%。所有 7 例复发均发生在无易位的肿瘤中。与经典 MN 相比,细胞型和混合型 MN 的 5 年 RFS 显著降低(89%、80%和 98%),而 5 年 OS 相似(93%、96%和 98%)。在细胞型 MN 组中,携带易位阳性肿瘤的患者的 RFS 显著更高(5 年 RFS:100% vs. 73%)。

结论

大多数细胞型 MN 携带 ETV6-NTKR3 基因融合,而经典型和混合型 MN 均为易位阴性。在细胞型亚组中,携带易位阳性肿瘤的患者的 RFS 显著更高。

相似文献

1
ETV6-NTRK3 in congenital mesoblastic nephroma: A report of the SIOP/GPOH nephroblastoma study.先天性中胚层肾瘤中的 ETV6-NTRK3:SIOP/GPOH 肾母细胞瘤研究报告。
Pediatr Blood Cancer. 2018 Apr;65(4). doi: 10.1002/pbc.26925. Epub 2017 Dec 29.
2
Cryptic t(12;15)(p13;q26) producing the ETV6-NTRK3 fusion gene and no loss of IGF2 imprinting in congenital mesoblastic nephroma with trisomy 11: fluorescence in situ hybridization and IGF2 allelic expression analysis.隐匿性t(12;15)(p13;q26)产生ETV6-NTRK3融合基因且11三体先天性中胚叶肾瘤中IGF2印记未丢失:荧光原位杂交及IGF2等位基因表达分析
Cancer Genet Cytogenet. 2002 Jul 1;136(1):10-6. doi: 10.1016/s0165-4608(02)00529-0.
3
Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma.先天性中胚层肾瘤t(12;15)与ETV6-NTRK3基因融合相关:与先天性(婴儿型)纤维肉瘤的细胞遗传学及分子关系
Am J Pathol. 1998 Nov;153(5):1451-8. doi: 10.1016/S0002-9440(10)65732-X.
4
Mixed epithelial and stromal tumor of the kidney lacks the genetic alterations of cellular congenital mesoblastic nephroma.肾脏混合性上皮和间质肿瘤缺乏细胞性先天性中胚层肾瘤的基因改变。
Hum Pathol. 2001 May;32(5):513-20. doi: 10.1053/hupa.2001.24323.
5
Congenital mesoblastic nephroma: a study of 19 cases using immunohistochemistry and ETV6-NTRK3 fusion gene rearrangement.先天性中胚层肾瘤:一项应用免疫组织化学和ETV6-NTRK3融合基因重排对19例病例的研究
Pathology. 2016 Jan;48(1):47-50. doi: 10.1016/j.pathol.2015.11.007. Epub 2015 Dec 18.
6
Duplication of the paternal IGF2 allele in trisomy 11 and elevated expression levels of IGF2 mRNA in congenital mesoblastic nephroma of the cellular or mixed type.11三体中父源IGF2等位基因的重复以及细胞型或混合型先天性中胚层肾瘤中IGF2 mRNA表达水平的升高。
Genes Chromosomes Cancer. 2007 Oct;46(10):929-35. doi: 10.1002/gcc.20481.
7
Congenital mesoblastic nephroma is characterised by kinase mutations including EGFR internal tandem duplications, the ETV6-NTRK3 fusion, and the rare KLHL7-BRAF fusion.先天性中胚层肾瘤的特征是激酶突变,包括 EGFR 内部串联重复、ETV6-NTRK3 融合,以及罕见的 KLHL7-BRAF 融合。
Histopathology. 2020 Oct;77(4):611-621. doi: 10.1111/his.14194. Epub 2020 Sep 10.
8
Expression of ETV6-NTRK in classical, cellular and mixed subtypes of congenital mesoblastic nephroma.
Histopathology. 2006 May;48(6):748-53. doi: 10.1111/j.1365-2559.2006.02400.x.
9
A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinoma.分泌型乳腺癌中ETV6-NTRK3融合基因的荧光原位杂交研究
Genes Chromosomes Cancer. 2004 Jun;40(2):152-7. doi: 10.1002/gcc.20028.
10
Detection of the ETV6-NTRK3 chimeric RNA of infantile fibrosarcoma/cellular congenital mesoblastic nephroma in paraffin-embedded tissue: application to challenging pediatric renal stromal tumors.石蜡包埋组织中婴儿纤维肉瘤/细胞性先天性中胚层肾瘤的ETV6-NTRK3嵌合RNA检测:在具有挑战性的小儿肾间质肿瘤中的应用
Mod Pathol. 2000 Jan;13(1):29-36. doi: 10.1038/modpathol.3880006.

引用本文的文献

1
Paediatric renal tumors: An insight into molecular characteristics, histomorphology and syndromic association.小儿肾肿瘤:对分子特征、组织形态学及综合征关联的深入见解
World J Nephrol. 2025 Jun 25;14(2):99380. doi: 10.5527/wjn.v14.i2.99380.
2
Poor outcome in congenital mesoblastic nephroma with fusion: a case report from multi-disciplinary treatment to molecular tumor board.先天性中胚层肾瘤伴融合的不良预后:从多学科治疗到分子肿瘤委员会的病例报告
Transl Pediatr. 2024 Jun 30;13(6):976-986. doi: 10.21037/tp-24-126. Epub 2024 Jun 27.
3
A Pathogenic Germline BRCA1 Variant in a Patient With Cellular Congenital Mesoblastic Nephroma: A Case Report.
一名患有细胞性先天性中胚层肾瘤患者的致病性胚系BRCA1变异:病例报告
Cureus. 2023 Aug 21;15(8):e43857. doi: 10.7759/cureus.43857. eCollection 2023 Aug.
4
Report and follow-up on two new patients with congenital mesoblastic nephroma.报告并随访 2 例先天性中胚层肾瘤新病例。
Ital J Pediatr. 2023 Sep 19;49(1):124. doi: 10.1186/s13052-023-01523-7.
5
Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors.日本肿瘤内科学会/日本临床肿瘤学会/日本小儿血液肿瘤学会:神经酪氨酸激酶受体融合阳性晚期实体瘤成人及儿科患者中肌球蛋白受体激酶抑制剂诊断及使用的临床推荐意见
Int J Clin Oncol. 2023 Jul;28(7):827-840. doi: 10.1007/s10147-023-02345-7. Epub 2023 May 22.
6
Molecular Markers of Pediatric Solid Tumors-Diagnosis, Optimizing Treatments, and Determining Susceptibility: Current State and Future Directions.儿科实体瘤的分子标志物——诊断、优化治疗和易感性评估:现状与未来方向。
Cells. 2022 Apr 6;11(7):1238. doi: 10.3390/cells11071238.
7
Cellular congenital mesoblastic nephroma detected by prenatal MRI: a case report and literature review.产前磁共振成像检测到的细胞性先天性中胚层肾瘤:一例报告并文献复习
Transl Pediatr. 2022 Jan;11(1):163-173. doi: 10.21037/tp-21-289.
8
The promise of TRK inhibitors in pediatric cancers with NTRK fusions.NTRK 融合阳性儿科肿瘤中 TRK 抑制剂的前景。
Cancer Genet. 2022 Apr;262-263:71-79. doi: 10.1016/j.cancergen.2022.01.004. Epub 2022 Jan 22.
9
Characteristics and outcome of children with renal tumors in the Netherlands: The first five-year's experience of national centralization.荷兰儿童肾肿瘤的特征和结局:国家集中化的头五年经验。
PLoS One. 2022 Jan 13;17(1):e0261729. doi: 10.1371/journal.pone.0261729. eCollection 2022.
10
[Diagnosis and therapy of tumors with NTRK gene fusion].[具有NTRK基因融合的肿瘤的诊断与治疗]
Pathologe. 2021 Feb;42(1):103-115. doi: 10.1007/s00292-020-00864-y.